Format

Send to

Choose Destination
Br J Psychiatry. 2013 Jun;202:428-33. doi: 10.1192/bjp.bp.112.124883. Epub 2013 Feb 21.

Computer-assisted therapy for medication-resistant auditory hallucinations: proof-of-concept study.

Author information

1
Department of Mental Health Sciences, Royal Free and University College Medical School, London, UK. j.leff@ucl.ac.uk

Erratum in

  • Br J Psychiatry. 2013 Oct;203:313.

Abstract

BACKGROUND:

One in four patients with schizophrenia responds poorly to antipsychotic medication, continuing to hear persecutory auditory hallucinations. Patients who are able to sustain a dialogue with their persecutor feel much more in control.

AIMS:

To develop a computerised system that enables the patient to create an avatar of their persecutor. To encourage them to engage in a dialogue with the avatar, which the therapist is able to control so that the avatar progressively yields control to the patient.

METHOD:

Avatar therapy was evaluated by a randomised, single blind, partial crossover trial comparing the novel therapy with treatment as usual (TAU). We used three main outcome measures: (a) the Psychotic Symptom Rating Scale (PSYRATS), hallucinations section; (b) the Omnipotence and Malevolence subscales of the Revised Beliefs About Voices Questionnaire (BAVQ-R); and (c) the Calgary Depression Scale (CDS).

RESULTS:

The control group showed no change over time in their scores on the three assessments, whereas the novel therapy group showed mean reductions in the total PSYRATS score (auditory hallucinations) of 8.75 (P = 0.003) and in the BAVQ-R combined score of omnipotence and malevolence of the voices of 5.88 (P = 0.004). There was no significant reduction in the CDS total score for depression. For the crossover control group, comparison of the period of TAU with the period of avatar therapy confirmed the findings of the previous analysis. The effect size of the therapy was 0.8.

CONCLUSIONS:

Avatar therapy represents a promising treatment for medication-resistant auditory hallucinations. Replication with a larger sample is required before roll-out to clinical settings.

Comment in

PMID:
23429202
DOI:
10.1192/bjp.bp.112.124883
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Cambridge University Press
Loading ...
Support Center